euro adhoc: Intercell AG / Annual Reports / Intercell presents 2006 Annual Report (E)

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

27.04.2007

Following a successful year, Intercell AG (VSE, "ICLL") today presents its
Annual Report 2006.

The illustrated Annual Report contains the audited consolidated financial
statements according to IFRS and gives detailed information on Intercell’s
latest achievements and anticipated milestones. It highlights the company’s
progress in product development and the scientific and commercial potential of
its technology platforms. At the same time, Intercell AG publishes its statutory
financial report according to Austrian GAAP.

The online version of the Annual Report is now available for download at
www.intercell.com. A hard copy can be requested at Intercell’s Communication
Department by mail([email protected]) or by phone (+43-1-20620-0).

About Intercell AG:

Intercell AG is a growing biotechnology company which focuses on the design and
Intercell AG is a growing biotechnology company which focuses on the design and
development of novel vaccines for the prevention and treatment of infectious
diseases with substantial unmet medical need. The Company develops antigens and
adjuvants which are derived from its proprietary technology platforms, and has
in-house GMP manufacturing capability. Based on these technologies, Intercell
has strategic partnerships with a number of global pharmaceutical companies,
including Novartis, Merck&Co., Wyeth, sanofi pasteur, Kirin and the Statens
Serum Institut.
The Company’s leading product, a prophylactic vaccine against Japanese
Encephalitis, successfully concluded pivotal Phase III clinical trials in 2006.
The regulatory process towards a Biologics License Application (BLA) to the U.S.
Food and Drug Administration (FDA) has been initiated. The broad development
pipeline includes a Pseudomonas vaccine in Phase II, a therapeutic vaccine for
Hepatitis C in Phase II, partnered vaccines for Tuberculosis and S.aureus which
are in Phase I, and five products focused on infectious diseases in preclinical
development. Intercell is listed on the Vienna stock exchange under the symbol
"ICLL".

For more information please visit: www.intercell.com

Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
[email protected]

end of announcement euro adhoc 27.04.2007 08:13:24
--------------------------------------------------------------------------------

emitter: Intercell AG
Campus Vienna Biocenter 6
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: [email protected]
WWW: www.intercell.com
sector: Biotechnology
ISIN: AT0000612601
indexes:
stockmarkets: official market: Wiener Börse AG
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | OTB

print